KR102373754B1 - 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제 - Google Patents

바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제 Download PDF

Info

Publication number
KR102373754B1
KR102373754B1 KR1020207017470A KR20207017470A KR102373754B1 KR 102373754 B1 KR102373754 B1 KR 102373754B1 KR 1020207017470 A KR1020207017470 A KR 1020207017470A KR 20207017470 A KR20207017470 A KR 20207017470A KR 102373754 B1 KR102373754 B1 KR 102373754B1
Authority
KR
South Korea
Prior art keywords
lif
cells
cytokine
cell
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207017470A
Other languages
English (en)
Korean (ko)
Other versions
KR20200078668A (ko
Inventor
후안 세오안 수아레즈
실비아 페누엘라스 프리에토
호세 바셀가 토레스
Original Assignee
인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠
펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론
펀다시오 호스피탈 유니버시타리 발 드헤브론-인스티튜트 디 레세르카
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠, 펀다시오 프리바다 인스티튜트 드인베스티가시오 온콜로지카 데 발 헤브론, 펀다시오 호스피탈 유니버시타리 발 드헤브론-인스티튜트 디 레세르카 filed Critical 인스티튜시오 카탈라나 드 르세르카 아이 에스투디스 아반카츠
Priority to KR1020227007752A priority Critical patent/KR20220035978A/ko
Publication of KR20200078668A publication Critical patent/KR20200078668A/ko
Application granted granted Critical
Publication of KR102373754B1 publication Critical patent/KR102373754B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
KR1020207017470A 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제 Active KR102373754B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227007752A KR20220035978A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ESP200900928 2009-04-03
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
KR1020197022597A KR20190093691A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197022597A Division KR20190093691A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227007752A Division KR20220035978A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Publications (2)

Publication Number Publication Date
KR20200078668A KR20200078668A (ko) 2020-07-01
KR102373754B1 true KR102373754B1 (ko) 2022-03-15

Family

ID=42342718

Family Applications (6)

Application Number Title Priority Date Filing Date
KR1020197022597A Ceased KR20190093691A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020177030504A Ceased KR20170121319A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020227007752A Ceased KR20220035978A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020207017470A Active KR102373754B1 (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020187018827A Ceased KR20180079470A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020117026088A Ceased KR20120100703A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Family Applications Before (3)

Application Number Title Priority Date Filing Date
KR1020197022597A Ceased KR20190093691A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020177030504A Ceased KR20170121319A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020227007752A Ceased KR20220035978A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187018827A Ceased KR20180079470A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
KR1020117026088A Ceased KR20120100703A (ko) 2009-04-03 2010-04-06 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제

Country Status (24)

Country Link
US (4) US10100112B2 (enExample)
EP (2) EP3045474B1 (enExample)
JP (5) JP6207836B2 (enExample)
KR (6) KR20190093691A (enExample)
CN (2) CN102574918A (enExample)
AU (1) AU2010233791B2 (enExample)
BR (1) BRPI1015369A2 (enExample)
CA (1) CA2757680C (enExample)
CY (1) CY1124148T1 (enExample)
DK (1) DK3045474T3 (enExample)
EA (1) EA201101450A1 (enExample)
ES (2) ES2363358B1 (enExample)
HR (1) HRP20210352T1 (enExample)
HU (1) HUE054196T2 (enExample)
IL (1) IL215467A (enExample)
LT (1) LT3045474T (enExample)
MX (1) MX336903B (enExample)
PL (1) PL3045474T3 (enExample)
PT (1) PT3045474T (enExample)
SG (2) SG175032A1 (enExample)
SI (1) SI3045474T1 (enExample)
SM (1) SMT202100153T1 (enExample)
WO (1) WO2010115868A2 (enExample)
ZA (1) ZA201107215B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3117833B1 (en) * 2005-07-19 2019-01-23 Stemgen S.P.A. Inhibition of the tumorigenic potential of tumor stem cells by lif
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
AU2015228386A1 (en) * 2014-03-11 2016-09-22 Godavari Biorefineries Limited Cancer stem cell targeting compounds
EP3160498B1 (en) * 2014-06-30 2021-10-06 Altor BioScience Corporation Il-15-based molecules and methods of use thereof
CA2958685A1 (en) * 2014-09-10 2016-03-17 The Regents Of The University Of California Targeting k-ras-mediated signaling pathways and malignancy by anti-hlif antibodies
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
EP3273983B1 (en) 2015-03-23 2021-05-05 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
MX2019007376A (es) 2016-12-19 2020-02-07 Mosaic Biomedicals S L U Anticuerpos contra el lif y usos de los mismos.
CN112638941A (zh) * 2018-05-14 2021-04-09 免疫医疗有限公司 针对lif的抗体及其剂量形式
JP7520727B2 (ja) * 2018-06-18 2024-07-23 メドイミューン・リミテッド 癌を有する個人における抗ｌｉｆ抗体治療に対する反応を向上させるための方法
WO2019243900A2 (en) * 2018-06-18 2019-12-26 Mosaic Biomedicals Slu Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
MX2021012163A (es) * 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
MC2115A1 (fr) 1987-12-15 1991-07-05 Gene Shears Pty Ltd Ribozynes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
RU2236251C2 (ru) * 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
CA2480052A1 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
JP2006512924A (ja) * 2002-08-15 2006-04-20 ジェンザイム・コーポレーション 脳内皮細胞発現パターン
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004067778A2 (en) * 2003-01-28 2004-08-12 University Of South Florida Differentially expressed genes in large granular lymphocyte leukemia
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
JP2012501188A (ja) * 2008-08-29 2012-01-19 ジェネンテック， インコーポレイテッド Ｖｅｇｆ非依存性腫瘍についての診断薬および治療
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Breast Cancer Res. 9(5): R69(2007)
Syst. Synth. Biol. 1(4): 171-181(2008.05.08.)

Also Published As

Publication number Publication date
US20120114671A1 (en) 2012-05-10
AU2010233791B2 (en) 2016-01-21
SG175032A1 (en) 2011-11-28
CA2757680C (en) 2021-11-02
US20200385455A1 (en) 2020-12-10
IL215467A0 (en) 2011-12-29
MX2011010425A (es) 2012-03-06
JP2019006784A (ja) 2019-01-17
PL3045474T3 (pl) 2021-08-09
WO2010115868A3 (en) 2011-02-03
US10100112B2 (en) 2018-10-16
KR20220035978A (ko) 2022-03-22
JP2020090522A (ja) 2020-06-11
DK3045474T3 (da) 2021-03-22
JP7197665B2 (ja) 2022-12-27
JP2012522756A (ja) 2012-09-27
SMT202100153T1 (it) 2021-05-07
CA2757680A1 (en) 2010-10-14
ES2363358A1 (es) 2011-08-01
SG10202010568RA (en) 2020-11-27
KR20180079470A (ko) 2018-07-10
HRP20210352T1 (hr) 2021-05-28
KR20170121319A (ko) 2017-11-01
JP6207836B2 (ja) 2017-10-04
KR20190093691A (ko) 2019-08-09
EA201101450A1 (ru) 2012-04-30
WO2010115868A2 (en) 2010-10-14
JP2016040255A (ja) 2016-03-24
PT3045474T (pt) 2021-03-22
JP2022031742A (ja) 2022-02-22
CN107964043A (zh) 2018-04-27
US11999782B2 (en) 2024-06-04
US20190211095A1 (en) 2019-07-11
EP3045474A2 (en) 2016-07-20
ES2363358B1 (es) 2012-06-21
IL215467A (en) 2016-06-30
US20240400667A1 (en) 2024-12-05
ES2864639T3 (es) 2021-10-14
EP3045474B1 (en) 2021-01-13
CN102574918A (zh) 2012-07-11
EP2414394A2 (en) 2012-02-08
KR20120100703A (ko) 2012-09-12
KR20200078668A (ko) 2020-07-01
LT3045474T (lt) 2021-05-10
SI3045474T1 (sl) 2021-07-30
CY1124148T1 (el) 2022-05-27
EP3045474A3 (en) 2016-09-28
HUE054196T2 (hu) 2021-08-30
MX336903B (es) 2016-02-04
ZA201107215B (en) 2012-12-27
AU2010233791A1 (en) 2011-11-03
BRPI1015369A2 (pt) 2021-06-29

Similar Documents

Publication Publication Date Title
US11999782B2 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
JP7410211B2 (ja) 望ましくない細胞増殖に関係する疾患の処置のための薬剤
HK1229338A1 (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1229338B (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
HK1172348A (en) Therapeutic agents for the treatment of diseases associated with undesired cell proliferation
EA040048B1 (ru) Фармацевтическая композиция и способ лечения глиомы, характеризущейся наличием высоких уровней lif

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200617

Application number text: 1020197022597

Filing date: 20190731

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200717

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201023

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210929

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201023

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210929

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210423

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20211207

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20211101

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210929

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210423

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220308

Application number text: 1020197022597

Filing date: 20190731

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220308

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220310

End annual number: 3

Start annual number: 1

PG1601 Publication of registration